Many stocks have been testing new highs in 2020, and one of the most notable is Momenta Pharmaceuticals Inc. (MNTA). Currently, MNTA is trading at $33.36 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $37.88.
To add more color to this target, the company’s high over the last year is $35.13 and the low is $9.51. Over the last 52 weeks, MNTA is down -5.04% while the S&P 500 is down -0.75%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, MNTA reported a profit of $49.56 million. Momenta Pharmaceuticals Inc. also saw revenues increase to $8.89 million. In addition, MNTA has free cash flow of -$65.47 million as of 03-2020 The company’s EBITDA came in at -$39.64 million which compares well with its peers.
MNTA Return on Equity (ROE) is -77.40%, and its Return on Assets is -55.20%. All told, it is clear that, MNTA needs to be on your watchlist.
Find out when MNTA reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. MNTA has a short ratio of 3.78 and outstanding shares of 117.13M.
MNTA has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.81 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -2.80. Momenta Pharmaceuticals Inc. MNTA also noted assets of $568.75 million at the end of the last quarter. Investors should also keep an eye on sector updates as MNTA has historically followed its peers on positive news.
All told, Momenta Pharmaceuticals Inc. MNTA has strung together solid data and demonstrated underlying fundamentals. At its current valuation, MNTA represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Momenta Pharmaceuticals Inc. MNTA is now commanding a market cap of 3.91B and a float of 116.60M. MNTA is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of MNTA stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in MNTA, either long or short, and we have not been compensated for this article.